AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near
Originator Has Previously Outlined 45% Erosion ‘Plus-Or-Minus 10%’
AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.
